The forecast of the import of cortisone, hydrocortisone, prednisone, and prednisolone into China shows a steady annual increase from 2024 through 2028, starting at USD 165,090 in 2024 and reaching USD 175,380 by 2028. Assuming the year 2023 had data available, a CAGR calculated over the forecast period would highlight a modest upward trend in imports, revealing a stable demand.

Future trends to watch for include:

Potential changes in China's healthcare policies impacting drug imports.
Fluctuations in global pharmaceutical supply chains affecting availability and pricing.
Advancements in domestic production capabilities potentially reducing reliance on imports.
Strengthening partnerships with international pharmaceutical companies.